Testing effectiveness (Phase 2)Active Not RecruitingNCT05215106
What this trial is testing
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Who this might be right for
Early Small (cT1N0) Triple Negative Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 200